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Thiazide diuretics have been first-line treatment for 
hypertension for over 30 years and their efficacy has 
been reinforced by recent trials, especially in elderly 
patients (Table 1) [1, 2|. However, almost from the 
lime of their introduction there has been concern
• reduction in peripheral sensitivity to insulin, again 
either as a direct effect or as a consequence of hypo- 
kalaemia and hypomagnesaemia [11—13].
It has also been suggested that hypokalaemia is an ag­
gravating factor rather than a primary stimulus in di-
about their metabolic effects, including hypokalae- uretic-associated hyperglycaemia [14],
mi a and other electrolyte disturbances. More contro- From the literature we have noted a striking simi-
versially, most but not all reports indicated that the larity of action on pancreatic beta cells and the vascu-
thia/.ides may impair glucose tolerance in non-dia- lar system of drugs that modulate potassium chan-
betic subjects [3] and can aggravate diabetes mellitus, nels. On the basis of these reports and of our own ex-
parlicularly in non-insulin-dependent (NIDDM) pa- periments on the vascular effects of hydrochlorothi-
tients [4]. This is generally regarded as a dose-related 
adverse effect [5, 0>| but there is also a temporal com­
ponent which has emerged during long-term follow- 
up of thiazide-treated patients |7]. The glucose intol­
erance is usually reversible after discontinuation of 
treatment [6, 8], though this may lake 6 months or 
more. It has been suggested that this 'wrong direc­
tion1 side-effect of thiazides could be one of (he rea-
azide and related compounds, we propose a novel hy­
pothesis regarding the mechanism of the diabetoge­
nic effects of thiazides.
In the pancreas, depolarization of the plasma mem­
brane by closure of potassium channels and opening 
of cation and chloride channels leads to a opening of 
voltage dependent calcium channels and influx of cal­
cium [15-17], The resultant increase of intracellular
sons of the relatively modest -  but slill significant -  calcium is crucial to the process of insulin release. Di- 
prolcclivc effect towards ischaemic heart disease [9], azoxide, a drug structurally related to the thiazides,
although there is no direct evidence for this view. hypcrpolarizes pancreatic beta cells by opening a spe
Although glucose intolerance may develop in cific class of ATP-dependent potassium (KA-n>) clian- 
about 3% of hypertensive patients treated with thiaz- nels and the consequent hyperpolarization impairs 
ide diuretics [6, tX] the mechanism underlying this side 
effect has only been sparsely studied and remains lar­
gely unknown. Several potential mechanisms have Table 1. Thiazides and thiazide-like diuretics in clinical use
been proposed. These can be grouped under two
• inhibition of insulin secretion by the beta cell, ei­
ther directly or secondary to hypokalaemia [4, 10]
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insulin release [18-20]. For this reason diazoxide is is usually commensurate with the fall in blood pres-
used in the management of hypoglycaemia due to in­
sulinoma. It is believed that the potassium channel- 
opening properties of diazoxide are also responsible 
for its vasorelaxant activity in vitro and in vivo [21, 
22]. Both pancreatic and vascular effects of diazoxide 
can be inhibited by sulphonylurea derivatives such as 
glibenclamide [19,20,23], which are used in NIDDM  
[24,25]. Sulphonylureas close KAXP channels resulting 
in depolarization of the beta-cell membrane, thereby
sure. However, with continued treatment the plasma 
volume tends to return to normal while the blood 
pressure reduction is maintained, implying that pe­
ripheral resistance must be diminished. Several re­
ports have supported this hypothesis by more direct 
estimation of the peripheral resistance [32]. The 
mechanism of the vascular effect is not understood.
Our group has been among the very few to study 
the acute vascular effects of the thiazides. In experi-
promoting an influx of calcium via the opening of volt- ments with isolated guinea-pig arteries and vessels
age-dependent calcium channels [19,20], Other open­
ers of the Katp channel, such as nicorandil and pinaci- 
dil, also inhibit insulin secretion [26, 27], although at 
concentrations much higher than required for smooth 
muscle cell relaxation. In fact, during clinical use nico-
from human subcutaneous fat we have found that hy­
drochlorothiazide relaxes vascular smooth muscle 
cells in clinically relevant concentrations [33] through 
inhibition of calcium influx [34]. This effect of hydro­
chlorothiazide is associated with an increase in H(1Rb +
randil does not significantly affect the plasma glucose efflux, a marker of K + efflux, [35] indicating that hy-
level [28]. By contrast, conventional thiazides do not 
interact with this type of potassium channel.
drochlorothiazide increases membrane permeability 
to K + ions, probably by opening K + channels. The ef­
fects of hydrochlorothiazide on vascular tone, [Ca2 + ]j 
and 86R b + efflux were inhibited by charybdotoxin 
and iberiotoxin, both relatively selective blockers of 
KCa channels [33, 34]. By contrast the KAT1, channel 
Like the KATP channel, the large-conductance cal- blocker glibenclamide, and apamin, a blocker of small
Calcium-activated potassium channels
cium-activated potassium (KCtt) channel is also ex­
pressed in both pancreatic beta cells [25] and vascular
conductance KCa channels, did not affect hydrochlo­
rothiazide-induced vasorelaxation or w,R b+ efflux 
smooth muscle cells [26]. In the beta cell of the rat the [35]. This is consistent with a previous report showing 
KCa channel can be blocked by quinine [25], although that hydrochlorothiazide does not affect the opening 
it must be stressed that quinine is not selective for of single KAT1> channels in the beta-cell plasma mem- 
these channels. In humans, treatment with quinine is brane [36]. These data suggest that the opening of
associated with hypoglycaemia due to stimulation of 
insulin release [27], presumably due at least in part
KCa channels rather than KAT!. channels mediates 
acute effects of thiazides on vascular smooth muscle
to inhibition of KCa channnels. Quinine is also known cells. Interestingly electrophysiological studies have
to cause inner ear disturbances including tinnitus, shown that cicletanine, a thiazide-like drug containing
hearing loss, and vertigo and this is thought to be a furopyridine group, causes membrane hyperpolari-
due at least in part to vasoconstriction [28] and conse- sation in isolated canine femoral arteries [37] proba-
quent ischaemia [29]. Such a hypothesis is consistent bly by an action on KCa channels. Since these channels
with the increasingly recognized role of KCn channels are present in pancreatic beta cells [25] and by analogy
in the regulation of vascular tone [30].
It has recently been reported that hydrochlorothi­
azide at low concentrations (0.1-1.0 (.imol/1) reduces 
insulin release in vitro. This was associated with a fall 
in glucose-stimulated 45Ca2+ uptake in beta cells [31]. 
As discussed above influx of calcium is one of the 
most distal steps in stimulus-secretion coupling in pan-
with the potassium channel opening properties of dia­
zoxide it is very likely that the effect of hydrochlo­
rothiazide on KCa channels would be to hyperpolarise 
the beta-cell membrane, leading to reduced insulin re­
lease. This effect could explain the inhibitory action of 
hydrochlorothiazide on insulin secretion.
At present it is unclear how thiazides act on
creatic beta cells and is crucial to insulin release [16]. KCachannels. It is possible that they interact directly 
As we will describe in the following section, the action with the KCa channel, but an indirect effect on the 
of hydrochlorothiazide on calcium influx into the pan- channel via an intracellular signalling mechanism is 
creatic beta cell shows a striking similarity with its ef- also possible. Ongoing studies in our department sug- 
fectoncalciumentryintovascularsmoothmusclecells. gest that the K + channel opening properties of hy­
drochlorothiazide may depend on changes in intrac­
ellular pH (pH;). Effects of hydrochlorothiazide on
New experimental data
The mechanism of the antihypertensive effect of the 
thiazides remains controversial. There is general
pHj appear, in turn, to be associated with the ability 
of the drug to inhibit carbonic anhydrase activity 
[38]. Others have shown that pre-treatment with ace- 
tazolamide, an inhibitor of carbonic anhydrase,
agreement that there is a reduction in plasma volume caused glucose intolerance in mice and reduced se- 
during the first l  or 2 weeks of thiazide therapy, which cretion of insulin in isolated pancreatic islets [39],
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2. This increases potassium permeability and causes 
hyperpolarisation of the membrane, inhibiting calci­
um influx through voltage-operated calcium channels.
3. The reduction in intracellular calcium attenuates 
insulin release by the beta cell.
We do not know if the interaction with this class of 
ion channels is a significant mechanism for the chron­
ic antihypertensive effects of the thiazides and we are 
not making any such proposal in our hypothesis. Our 
in vitro studies relate to acute responses to relatively 
high drug concentrations and may be of limited rele­
vance for drugs which take weeks to achieve their 
maximal blood pressure-lowering effects. On the 
other hand it is known for the thiazide-like drug ind- 
apamide that during chronic treatment accumulation 
of the drug in the vascular smooth muscle cell takes 
place to levels 9 times greater than the plasma con­
centration [40].
It is entirely possible that other, peripheral, diabe­
togenic actions of thiazides may be important. How- 
although no human data is available for this drug. ever, we believe that ours is a plausible hypothesis. It 
However, it should be emphasised that direct evi- raises the possibility that thiazides or thiazide-like 
denee concerning the role of carbonic anhydrase in- drugs can be developed with few if any metabolic 
hibiting activity is lacking, though we have found the side-effects. Indapamide is structurally related to the 
vasorelaxant action of beiKlroflumothiazide, a very thiazides but does not interact with KCil and KATP chan- 
weak inhibitor of carbonic anhydrase [38], to be nels [33] and has less effect on glucose, lipid and uric
Fig. 1. Representation of hypothesis. Activation of ATP-sensi- 
tive potassium channels (KAT1. ) or of large-aniplitude calcium- 
activaled potassium channels ( K, ) increase potassium conduc­
tance and hyperpolarise the cell membrane in the pancreatic 
beta cells, thereby reducing calcium entry through voltage-op- 
eraled calcium channels (VC)C’) and so inhibiting insulin secre­
tion
much smaller than that of aceta/.olamide and hydro acid homeostasis [41 ]. Its exact mode of action remains
chlorothiazide and this action was not inhibited by uncertain, though it may act partly through blockade 
eharybdotoxin. This suggests that bendroflumethiaz- of voltage-operated calcium channels [33, 42],
ide does not act on Kr., channels.
Summary and hypothesis
We can therefore summarise the following experi­
mental findings, partly from our own studies and part­
ly from the work of other groups:
• calcium influx is an essential component in stimu- 
lus-seeretion coupling in pancreatic bela-cells and ex- 
citation-contraction coupling in vascular smooth 
muscle cells
• thiazides inhibit calcium influx in these cells
• thiazides (e.g. lOjimol/l hydrochlorothiazide) also 
inhibit calcium entrv in small mesenteric arteries
*
• in vascular smooth muscle thiazides increase potas­
sium permeability probably via large conductance Kn, 
channels, resulting in membrane hyperpolarisation 
and the closure of voltage-operated calcium channels.
We therefore propose the hypothesis illustrated in 
Figure 1 as an explanation for al least part of the ad­
verse effect of thiazides on glucose homeostasis: in 
the absence of direct experimental evidence it omits 
mention of the possible role of carbonic anhydrase in­
hibition. In summary:
V
I. Thiazide diuretics directly or indirectly open the 
large-eonduetanee Kra channel in the plasma mem­
brane ol‘ the pancreatic beta cell.
It should be noted that attempts have been made 
to synthesise compounds speeificially intended to in­
teract with Kr,( channels, but to date these are neither 
potent nor selective [43],
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